A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis

• Published in: Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2020-01, Vol.72 (1), p.47-56
• Main Authors: Bach, Mary, Moon, Jeonghun, Moore, Richard, Pan, Tiffany, Nelson, J. Lee, Lood, Christian
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Anti-Citrullinated Protein Antibodies - immunology; Antibodies; Apoptosis; Arthritis; Arthritis, Rheumatoid - diagnostic imaging; Arthritis, Rheumatoid - immunology; Autoimmunity; Biomarkers; C-Reactive Protein - immunology; Case-Control Studies; Cell activation; Cell Death; Citrulline; Extracellular Traps - microbiology; Female; Humans; Inflammation; Interleukin-6 - immunology; Leukocyte L1 Antigen Complex - immunology; Leukocytes (neutrophilic); Longitudinal Studies; Male; Middle Aged; Monitoring; Mortality; Neutrophil Activation - immunology; Neutrophils; Nodules; Patients; Prognosis; Proteins; Remission; Rheumatoid arthritis; Young Adult
• ISSN: 2326-5191; 2326-5205
• DOI: 10.1002/art.41062

Objective Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs) are linked to inflammation and autoimmunity, including rheumatoid arthritis (RA). However, whether NETs are present in the circulation of RA patients and contribute to inflammation and disease progression has not been carefully addressed. We undertook this study to assess markers of neutrophil activation and NET formation in plasma samples, investigating whether they add clinical value in improving the determination of prognosis and monitoring in RA patients. Methods Markers of neutrophil activation (calprotectin) and cell death (NETs) were analyzed, using enzyme‐linked immunosorbent assay, in serum and plasma obtained from patients in 3 cross‐sectional RA cohorts and sex‐matched healthy controls. A longitudinal inception cohort (n = 247), seen for a median follow‐up of 8 years, was used for predictive analyses. Results Markers of neutrophil activation and cell death were increased in RA patients compared to healthy individuals (P < 0.0001). Calprotectin levels correlated with the Clinical Disease Activity Index (r = 0.53, P < 0.0001) and could be used to distinguish between patients with disease in remission and those with active disease, an observation not seen when examining C‐reactive protein levels. A biomarker panel consisting of anti–citrullinated protein antibody and calprotectin could predict erosive disease (odds ratio [OR] 7.5, P < 0.0001) and joint space narrowing (OR 4.9, P = 0.001). NET levels were associated with markers of inflammation (P = 0.0002). Furthermore, NETs and a “neutrophil activation signature” biomarker panel had good predictive value in identifying patients who were developing extraarticular nodules (OR 5.6, P = 0.006). Conclusion Neutrophils undergo marked activation and cell death in RA. Neutrophil biomarkers can provide added clinical value in the monitoring and prognosis of RA patients and may allow for early preventive treatment intervention.